DrugPatentWatch Database Preview
LITHOTABS Drug Profile
Which patents cover Lithotabs, and when can generic versions of Lithotabs launch?
Lithotabs is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in LITHOTABS is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for LITHOTABS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 69 |
| Patent Applications: | 101 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LITHOTABS at DailyMed |
Medical Subject Heading (MeSH) Categories for LITHOTABS
Synonyms for LITHOTABS
| 10377-37-4 (mono-lithium salt) |
| 12767-19-0 |
| 1312765-65-3 |
| 216964-61-3 |
| 2BMD2GNA4V |
| 554-13-2 |
| AC1L1WO8 |
| AC1LANIP |
| AC1Q1U57 |
| ACMC-209lmw |
| AKOS015904647 |
| AN-45875 |
| ANGC-554-13-2 |
| ANW-32310 |
| B7705 |
| C07964 |
| Camcolit |
| Candamide |
| Carbolite |
| Carbolith |
| Carbolithium |
| Carbolithium IFI |
| Carbolitium |
| Carbonic Acid Dilithium Salt |
| Carbonic acid lithium salt |
| Carbonic acid lithium salt (Li2CO3) |
| Carbonic acid, dilithium salt |
| Carbonic acid, lithium salt |
| Carbonic acid, lithium salt (1:2) |
| CCRIS 3153 |
| Ceglution |
| CHEBI:6504 |
| CHEMBL1200826 |
| Cibalith-e |
| CLi2O3 |
| CP 15467-61 |
| CP-15,467-61 |
| CP-15467-61 |
| CP-1546761 |
| CTK1G9703 |
| D00801 |
| D04UUH |
| Dilithium carbonate |
| Dilithium Carbonate, Dilithium Salt, Carbonic Acid |
| dilithium trioxidocarbonate |
| dilithium(1+) ion carbonate |
| diLithoTab CO3 |
| Dilthium Carbonate |
| DTXSID1023784 |
| Duralite |
| EC 209-062-5 |
| EINECS 209-062-5 |
| Eskalite |
| Eskalith |
| Eskalith (TN) |
| Eskalith CR |
| Eutimin |
| FT-0627895 |
| GK3300 |
| HSDB 3351 |
| Hypnorex |
| I14-16784 |
| I494 |
| IN000219 |
| IN006073 |
| KS-0000025D |
| KSC269O0H |
| L0224 |
| Li2CO3 |
| Limas |
| Liskonum |
| Litard |
| Lithane |
| Lithea |
| Lithicarb |
| Lithinate |
| Lithionate |
| LITHIUM CARBONATE |
| Lithium carbonate (2:1) |
| Lithium carbonate (JP17/USP) |
| Lithium carbonate (Li2CO3) |
| Lithium carbonate [USAN:JAN] |
| Lithium carbonate [USAN:USP:JAN] |
| Lithium carbonate, 99% 500g |
| LITHIUM CARBONATE, ACS |
| Lithium carbonicum |
| Lithium Phasal |
| Lithium QD |
| Lithium, Reference Standard Solution |
| Lithiumcarbonat |
| Lithiumcarbonate |
| Lithizine |
| Litho-Carb |
| Lithobid |
| Lithobid (TN) |
| Lithobie |
| Lithonate |
| Lithotabs Priadee |
| Liticar |
| LS-88061 |
| LTBB002486 |
| Manialith |
| Maniprex |
| MFCD00011084 |
| Micalith |
| MolPort-003-927-648 |
| Neurolepsin |
| NSC-16895 |
| OR284070 |
| Pfi-lithium |
| Pfl-Lithium |
| Phasal |
| Plenur |
| Priadel |
| Quilonorm |
| Quilonum retard |
| RL04084 |
| RTR-019539 |
| Teralithe |
| Teralithe [French] |
| TR-019539 |
| TRA0065195 |
| UNII-2BMD2GNA4V |
| XGZVUEUWXADBQD-UHFFFAOYSA-L |
| Zabuyelite |
US Patents and Regulatory Information for LITHOTABS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | LITHOTABS | lithium carbonate | TABLET;ORAL | 016980-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
